APO Research
Talk to an analyst

APO RESEARCH · REPORT

PD-1 and PD-L1 Inhibitors

PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.

Selected research

Market Structure

Global PD-1 and PD-L1 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025191 pages

Choose your research edition.

Industry ResearchPD-1 and PD-L1 Inhibitors Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal PD-1 and PD-L1 Inhibitors Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal PD-1 and PD-L1 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PD-1 and PD-L1 Inhibitors Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal PD-1 and PD-L1 Inhibitors Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.

North America is the largest consumption place, with a consumption market share nearly 60.40% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 20.66%.Market competition is intense. Merck, Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical etc. are the leaders of the industry.

This report provides an overview of the global PD-1 and PD-L1 Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of PD-1 and PD-L1 Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PD-1 and PD-L1 Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the PD-1 and PD-L1 Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

PD-1 and PD-L1 Inhibitors Segment by Company

Merck

Bristol-Myers Squibb

Roche

AstraZeneca

Ono Pharmaceutical

Regeneron

Innovent

Hengrui Medicine

Junshi Biosciences

Merck KGaA

PD-1 and PD-L1 Inhibitors Segment by Type

PD-1 Inhibitors

PD-L1 Inhibitors

PD-1 and PD-L1 Inhibitors Segment by Application

Solid Tumors

Blood-related Tumors

PD-1 and PD-L1 Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-1 and PD-L1 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PD-1 and PD-L1 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-1 and PD-L1 Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the PD-1 and PD-L1 Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of PD-1 and PD-L1 Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of PD-1 and PD-L1 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of PD-1 and PD-L1 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. PD-1 and PD-L1 Inhibitors Industry Trends Table 2. PD-1 and PD-L1 Inhibitors Industry Drivers Table 3. PD-1 and PD-L1 Inhibitors Industry Opportunities and Challenges Table 4. PD-1 and PD-L1 Inhibitors Industry Restraints Table 5. Global PD-1 and PD-L1 Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 7. Global PD-1 and PD-L1 Inhibitors Sales by Manufacturers (L) & (2021-2026) Table 8. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Manufacturers Table 9. Global PD-1 and PD-L1 Inhibitors Average Sales Price (USD/ml) of Manufacturers (2021-2026) Table 10. Global PD-1 and PD-L1 Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global PD-1 and PD-L1 Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global PD-1 and PD-L1 Inhibitors Manufacturers, Product Type & Application Table 13. Global PD-1 and PD-L1 Inhibitors Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global PD-1 and PD-L1 Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of PD-1 Inhibitors Table 17. Major Manufacturers of PD-L1 Inhibitors Table 18. Global PD-1 and PD-L1 Inhibitors Sales by Type 2021 VS 2025 VS 2032 (L) Table 19. Global PD-1 and PD-L1 Inhibitors Sales by Type (2021-2026) & (L) Table 20. Global PD-1 and PD-L1 Inhibitors Sales by Type (2027-2032) & (L) Table 21. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2021-2026) Table 22. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2027-2032) Table 23. Global PD-1 and PD-L1 Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (L) Table 24. Global PD-1 and PD-L1 Inhibitors Revenue by Type (2021-2026) & (L) Table 25. Global PD-1 and PD-L1 Inhibitors Revenue by Type (2027-2032) & (L) Table 26. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2021-2026) Table 27. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Solid Tumors Table 29. Major Manufacturers of Blood-related Tumors Table 30. Global PD-1 and PD-L1 Inhibitors Sales by Application 2021 VS 2025 VS 2032 (L) Table 31. Global PD-1 and PD-L1 Inhibitors Sales by Application (2021-2026) & (L) Table 32. Global PD-1 and PD-L1 Inhibitors Sales by Application (2027-2032) & (L) Table 33. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2021-2026) Table 34. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2027-2032) Table 35. Global PD-1 and PD-L1 Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (L) Table 36. Global PD-1 and PD-L1 Inhibitors Revenue by Application (2021-2026) & (L) Table 37. Global PD-1 and PD-L1 Inhibitors Revenue by Application (2027-2032) & (L) Table 38. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2021-2026) Table 39. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2027-2032) Table 40. Global PD-1 and PD-L1 Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (L) Table 41. Global PD-1 and PD-L1 Inhibitors Sales by Region (2021-2026) & (L) Table 42. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Region (2021-2026) Table 43. Global PD-1 and PD-L1 Inhibitors Sales Forecasted by Region (2027-2032) & (L) Table 44. Global PD-1 and PD-L1 Inhibitors Sales Forecasted Market Share by Region (2027-2032) Table 45. North America PD-1 and PD-L1 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (L) Table 46. North America PD-1 and PD-L1 Inhibitors Sales by Country (2021-2026) & (L) Table 47. North America PD-1 and PD-L1 Inhibitors Sales by Country (2027-2032) & (L) Table 48. Europe PD-1 and PD-L1 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (L) Table 49. Europe PD-1 and PD-L1 Inhibitors Sales by Country (2021-2026) & (L) Table 50. Europe PD-1 and PD-L1 Inhibitors Sales by Country (2027-2032) & (L) Table 51. Asia Pacific PD-1 and PD-L1 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (L) Table 52. Asia Pacific PD-1 and PD-L1 Inhibitors Sales by Country (2021-2026) & (L) Table 53. Asia Pacific PD-1 and PD-L1 Inhibitors Sales by Country (2027-2032) & (L) Table 54. South America, Middle East and Africa PD-1 and PD-L1 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (L) Table 55. South America, Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Country (2021-2026) & (L) Table 56. South America, Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Country (2027-2032) & (L) Table 57. Global PD-1 and PD-L1 Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global PD-1 and PD-L1 Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 59. Global PD-1 and PD-L1 Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 60. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Region (2021-2026) Table 61. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Region (2027-2032) Table 62. Merck Company Information Table 63. Merck Business Overview Table 64. Merck PD-1 and PD-L1 Inhibitors Sales (L), Price (USD/ml), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Merck PD-1 and PD-L1 Inhibitors Product Portfolio Table 66. Merck Recent Development Table 67. Bristol-Myers Squibb Company Information Table 68. Bristol-Myers Squibb Business Overview Table 69. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales (L), Price (USD/ml), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product Portfolio Table 71. Bristol-Myers Squibb Recent Development Table 72. Roche Company Information Table 73. Roche Business Overview Table 74. Roche PD-1 and PD-L1 Inhibitors Sales (L), Price (USD/ml), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Roche PD-1 and PD-L1 Inhibitors Product Portfolio Table 76. Roche Recent Development Table 77. AstraZeneca Company Information Table 78. AstraZeneca Business Overview Table 79. AstraZeneca PD-1 and PD-L1 Inhibitors Sales (L), Price (USD/ml), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. AstraZeneca PD-1 and PD-L1 Inhibitors Product Portfolio Table 81. AstraZeneca Recent Development Table 82. Ono Pharmaceutical Company Information Table 83. Ono Pharmaceutical Business Overview Table 84. Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales (L), Price (USD/ml), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Product Portfolio Table 86. Ono Pharmaceutical Recent Development Table 87. Regeneron Company Information Table 88. Regeneron Business Overview Table 89. Regeneron PD-1 and PD-L1 Inhibitors Sales (L), Price (USD/ml), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Regeneron PD-1 and PD-L1 Inhibitors Product Portfolio Table 91. Regeneron Recent Development Table 92. Innovent Company Information Table 93. Innovent Business Overview Table 94. Innovent PD-1 and PD-L1 Inhibitors Sales (L), Price (USD/ml), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Innovent PD-1 and PD-L1 Inhibitors Product Portfolio Table 96. Innovent Recent Development Table 97. Hengrui Medicine Company Information Table 98. Hengrui Medicine Business Overview Table 99. Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales (L), Price (USD/ml), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Hengrui Medicine PD-1 and PD-L1 Inhibitors Product Portfolio Table 101. Hengrui Medicine Recent Development Table 102. Junshi Biosciences Company Information Table 103. Junshi Biosciences Business Overview Table 104. Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales (L), Price (USD/ml), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Junshi Biosciences PD-1 and PD-L1 Inhibitors Product Portfolio Table 106. Junshi Biosciences Recent Development Table 107. Merck KGaA Company Information Table 108. Merck KGaA Business Overview Table 109. Merck KGaA PD-1 and PD-L1 Inhibitors Sales (L), Price (USD/ml), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Merck KGaA PD-1 and PD-L1 Inhibitors Product Portfolio Table 111. Merck KGaA Recent Development Table 112. Key Raw Materials Table 113. Raw Materials Key Suppliers Table 114. PD-1 and PD-L1 Inhibitors Distributors List Table 115. PD-1 and PD-L1 Inhibitors Customers List Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. PD-1 and PD-L1 Inhibitors Product Image Figure 2. Global PD-1 and PD-L1 Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PD-1 and PD-L1 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global PD-1 and PD-L1 Inhibitors Sales (2021-2032) & (L) Figure 5. Global PD-1 and PD-L1 Inhibitors Average Price (USD/ml) & (2021-2032) Figure 6. Global Top 5 and 10 PD-1 and PD-L1 Inhibitors Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. PD-1 Inhibitors Image Figure 9. PD-L1 Inhibitors Image Figure 10. Global PD-1 and PD-L1 Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (L) Figure 11. Global PD-1 and PD-L1 Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2021-2032) Figure 13. Global PD-1 and PD-L1 Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (L) Figure 14. Global PD-1 and PD-L1 Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2021-2032) Figure 16. Solid Tumors Image Figure 17. Blood-related Tumors Image Figure 18. Global PD-1 and PD-L1 Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (L) Figure 19. Global PD-1 and PD-L1 Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2021-2032) Figure 21. Global PD-1 and PD-L1 Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (L) Figure 22. Global PD-1 and PD-L1 Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2021-2032) Figure 24. North America PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 25. North America PD-1 and PD-L1 Inhibitors Sales Market Share by Country (2021-2032) Figure 26. U.S. PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 27. Canada PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 28. Mexico PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 29. Europe PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 30. Europe PD-1 and PD-L1 Inhibitors Sales Market Share by Country (2021-2032) Figure 31. Germany PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 32. France PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 33. U.K. PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 34. Italy PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 35. Netherlands PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 36. Asia Pacific PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 37. Asia Pacific PD-1 and PD-L1 Inhibitors Sales Market Share by Country (2021-2032) Figure 38. China PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 39. Japan PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 40. South Korea PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 41. Southeast Asia PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 42. India PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 43. Australia PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 44. South America, Middle East and Africa PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 45. South America, Middle East and Africa PD-1 and PD-L1 Inhibitors Sales Market Share by Country (2021-2032) Figure 46. Brazil PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 47. South Africa PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 48. Saudi Arabia PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 49. Turkey PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 50. Argentina PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 51. UAE PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 52. Egypt PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 53. Chile PD-1 and PD-L1 Inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 54. Global PD-1 and PD-L1 Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 57. North America PD-1 and PD-L1 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 59. Europe PD-1 and PD-L1 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific PD-1 and PD-L1 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. PD-1 and PD-L1 Inhibitors Value Chain Figure 65. Manufacturing Cost Structure Figure 66. PD-1 and PD-L1 Inhibitors Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • PD-1 Inhibitors
  • PD-L1 Inhibitors
Applications
  • Solid Tumors
  • Blood-related Tumors
Companies covered
  • Merck
  • Bristol-Myers Squibb
  • Roche
  • AstraZeneca
  • Ono Pharmaceutical
  • Regeneron
  • Innovent
  • Hengrui Medicine
  • Junshi Biosciences
  • Merck KGaA

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global PD-1 and PD-L1 Inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global PD-1 and PD-L1 Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global PD-1 and PD-L1 Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global PD-1 and PD-L1 Inhibitors Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global PD-1 and PD-L1 Inhibitors Market Dynamics
  1. 2.1 PD-1 and PD-L1 Inhibitors Industry Trends
  2. 2.2 PD-1 and PD-L1 Inhibitors Industry Drivers
  3. 2.3 PD-1 and PD-L1 Inhibitors Industry Opportunities and Challenges
  4. 2.4 PD-1 and PD-L1 Inhibitors Industry Restraints
3 PD-1 and PD-L1 Inhibitors Market by Manufacturers
  1. 3.1 Global PD-1 and PD-L1 Inhibitors Revenue by Manufacturers (2021-2026)
  2. 3.2 Global PD-1 and PD-L1 Inhibitors Sales by Manufacturers (2021-2026)
  3. 3.3 Global PD-1 and PD-L1 Inhibitors Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global PD-1 and PD-L1 Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global PD-1 and PD-L1 Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global PD-1 and PD-L1 Inhibitors Manufacturers, Product Type & Application
  7. 3.7 Global PD-1 and PD-L1 Inhibitors Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global PD-1 and PD-L1 Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 PD-1 and PD-L1 Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 PD-1 and PD-L1 Inhibitors Tier 1, Tier 2, and Tier 3
4 PD-1 and PD-L1 Inhibitors Market by Type
  1. 4.1 PD-1 and PD-L1 Inhibitors Type Introduction
  2. 4.1.1 PD-1 Inhibitors
  3. 4.1.2 PD-L1 Inhibitors
  4. 4.2 Global PD-1 and PD-L1 Inhibitors Sales by Type
  5. 4.2.1 Global PD-1 and PD-L1 Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global PD-1 and PD-L1 Inhibitors Sales by Type (2021-2032)
  7. 4.2.3 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2021-2032)
  8. 4.3 Global PD-1 and PD-L1 Inhibitors Revenue by Type
  9. 4.3.1 Global PD-1 and PD-L1 Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global PD-1 and PD-L1 Inhibitors Revenue by Type (2021-2032)
  11. 4.3.3 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2021-2032)
5 PD-1 and PD-L1 Inhibitors Market by Application
  1. 5.1 PD-1 and PD-L1 Inhibitors Application Introduction
  2. 5.1.1 Solid Tumors
  3. 5.1.2 Blood-related Tumors
  4. 5.2 Global PD-1 and PD-L1 Inhibitors Sales by Application
  5. 5.2.1 Global PD-1 and PD-L1 Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global PD-1 and PD-L1 Inhibitors Sales by Application (2021-2032)
  7. 5.2.3 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2021-2032)
  8. 5.3 Global PD-1 and PD-L1 Inhibitors Revenue by Application
  9. 5.3.1 Global PD-1 and PD-L1 Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global PD-1 and PD-L1 Inhibitors Revenue by Application (2021-2032)
  11. 5.3.3 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2021-2032)
6 Global PD-1 and PD-L1 Inhibitors Sales by Region
  1. 6.1 Global PD-1 and PD-L1 Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global PD-1 and PD-L1 Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global PD-1 and PD-L1 Inhibitors Sales by Region (2021-2026)
  4. 6.2.2 Global PD-1 and PD-L1 Inhibitors Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America PD-1 and PD-L1 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America PD-1 and PD-L1 Inhibitors Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe PD-1 and PD-L1 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe PD-1 and PD-L1 Inhibitors Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific PD-1 and PD-L1 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific PD-1 and PD-L1 Inhibitors Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa PD-1 and PD-L1 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global PD-1 and PD-L1 Inhibitors Revenue by Region
  1. 7.1 Global PD-1 and PD-L1 Inhibitors Revenue by Region
  2. 7.1.1 Global PD-1 and PD-L1 Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global PD-1 and PD-L1 Inhibitors Revenue by Region (2021-2026)
  4. 7.1.3 Global PD-1 and PD-L1 Inhibitors Revenue by Region (2027-2032)
  5. 7.1.4 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America PD-1 and PD-L1 Inhibitors Revenue (2021-2032)
  8. 7.2.2 North America PD-1 and PD-L1 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe PD-1 and PD-L1 Inhibitors Revenue (2021-2032)
  11. 7.3.2 Europe PD-1 and PD-L1 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific PD-1 and PD-L1 Inhibitors Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific PD-1 and PD-L1 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck PD-1 and PD-L1 Inhibitors Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Bristol-Myers Squibb
  8. 8.2.1 Bristol-Myers Squibb Company Information
  9. 8.2.2 Bristol-Myers Squibb Business Overview
  10. 8.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product Portfolio
  12. 8.2.5 Bristol-Myers Squibb Recent Developments
  13. 8.3 Roche
  14. 8.3.1 Roche Company Information
  15. 8.3.2 Roche Business Overview
  16. 8.3.3 Roche PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Roche PD-1 and PD-L1 Inhibitors Product Portfolio
  18. 8.3.5 Roche Recent Developments
  19. 8.4 AstraZeneca
  20. 8.4.1 AstraZeneca Company Information
  21. 8.4.2 AstraZeneca Business Overview
  22. 8.4.3 AstraZeneca PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca PD-1 and PD-L1 Inhibitors Product Portfolio
  24. 8.4.5 AstraZeneca Recent Developments
  25. 8.5 Ono Pharmaceutical
  26. 8.5.1 Ono Pharmaceutical Company Information
  27. 8.5.2 Ono Pharmaceutical Business Overview
  28. 8.5.3 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Product Portfolio
  30. 8.5.5 Ono Pharmaceutical Recent Developments
  31. 8.6 Regeneron
  32. 8.6.1 Regeneron Company Information
  33. 8.6.2 Regeneron Business Overview
  34. 8.6.3 Regeneron PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Regeneron PD-1 and PD-L1 Inhibitors Product Portfolio
  36. 8.6.5 Regeneron Recent Developments
  37. 8.7 Innovent
  38. 8.7.1 Innovent Company Information
  39. 8.7.2 Innovent Business Overview
  40. 8.7.3 Innovent PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Innovent PD-1 and PD-L1 Inhibitors Product Portfolio
  42. 8.7.5 Innovent Recent Developments
  43. 8.8 Hengrui Medicine
  44. 8.8.1 Hengrui Medicine Company Information
  45. 8.8.2 Hengrui Medicine Business Overview
  46. 8.8.3 Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Hengrui Medicine PD-1 and PD-L1 Inhibitors Product Portfolio
  48. 8.8.5 Hengrui Medicine Recent Developments
  49. 8.9 Junshi Biosciences
  50. 8.9.1 Junshi Biosciences Company Information
  51. 8.9.2 Junshi Biosciences Business Overview
  52. 8.9.3 Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Junshi Biosciences PD-1 and PD-L1 Inhibitors Product Portfolio
  54. 8.9.5 Junshi Biosciences Recent Developments
  55. 8.10 Merck KGaA
  56. 8.10.1 Merck KGaA Company Information
  57. 8.10.2 Merck KGaA Business Overview
  58. 8.10.3 Merck KGaA PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Merck KGaA PD-1 and PD-L1 Inhibitors Product Portfolio
  60. 8.10.5 Merck KGaA Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 PD-1 and PD-L1 Inhibitors Value Chain Analysis
  2. 9.1.1 PD-1 and PD-L1 Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 PD-1 and PD-L1 Inhibitors Production Mode & Process
  6. 9.2 PD-1 and PD-L1 Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 PD-1 and PD-L1 Inhibitors Distributors
  9. 9.2.3 PD-1 and PD-L1 Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst